PODD Share Price Performance
US$196.93
-58.54 (-22.91%)
54.7% undervalued intrinsic discount
US$435.00
Fair Value
Price US$196.93
AnalystHighTarget US$435.00
AnalystConsensusTarget US$351.43
Fair ValueUS$435.00
Share Pricen/a
Insulet Corporation Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
PODD Community Narratives
AN
Fair Value US$435 54.7% undervalued intrinsic discount
Long-Term Diabetes Automation Adoption And Manufacturing Scale Will Drive Strong Future Potential
1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$340.26 42.1% undervalued intrinsic discount
Digital Diabetes Care Will Expand International Market Opportunities
0users have liked this narrative
1users have commented on this narrative
17users have followed this narrative
Digital Diabetes Care Will Expand International Market Opportunities
Key Takeaways Expanding market share through strong adoption of Omnipod 5, entry into new segments, and broadened international reach is driving significant, sustained revenue growth and margin improvement. Increased accessibility, digital health integration, and widespread reimbursement are fueling stable utilization, high customer retention, and durable recurring revenue streams.Read more
281
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
17users have followed this narrative
AN
US$340.26
42.1% undervalued intrinsic discount
Fair Value
Revenue
19.71% p.a.
Profit Margin
15.43%
Future PE
41.78x
Price in 2029
US$425.14
Long-Term Diabetes Automation Adoption And Manufacturing Scale Will Drive Strong Future Potential
Catalysts About Insulet Insulet provides tubeless automated insulin delivery systems through its Omnipod platform for people living with diabetes worldwide. What are the underlying business or industry changes driving this perspective?Read more
7
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$435
54.7% undervalued intrinsic discount
Fair Value
Revenue
22.73% p.a.
Profit Margin
15.82%
Future PE
48.67x
Price in 2029
US$546.97
Trending Discussion
Recently Updated Narratives
AN
PODD: Type 2 Automation And New Markets Will Offset Patch Pump Competition
Fair Value: US$340.26 42.1% undervalued intrinsic discount
17 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long-Term Diabetes Automation Adoption And Manufacturing Scale Will Drive Strong Future Potential
Fair Value: US$435 54.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Insulet Corporation Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 06, 2026
- 3.57
- 71.63%
- 9.12%
- 62.8%
About PODD
- Founded
- 2000
- Employees
- 5400
- CEO
- WebsiteView website
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
